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BACKGROUND: The combination of temozolomide (TMZ) and irinotecan is a regimen used in neuroblastoma patients with recurrent
disease. O
6-methylguanine-DNA methyltransferase (MGMT) may have a function in resistance to TMZ. Using neuroblastoma pre-
clinical models, we determined whether the inhibition of MGMT by O
6-benzylguanine (O6-BG) could enhance the anti-tumour
activity of TMZ and irinotecan.
METHODS: The cytotoxicity of TMZ and irinotecan, either alone or in combination, was measured in five neuroblastoma cell lines in the
presence or absence of O6-BG with a fluorescence-based cell viability assay (DIMSCAN). Anti-tumour activity was measured in
three neuroblastoma xenograft models.
RESULTS: MGMT mRNA and protein were expressed in 9 out of 10 examined cell lines. Pretreatment of cells with 25mM O6-BG
decreased MGMT protein expression and enhanced The TMZ cytotoxicity by up to 0.3–1.4 logs in four out of five tested cell lines.
TMZ (25mgkg
 1 per day for 5 days every 3 weeks for four cycles) did not significantly improve mice survival, whereas the same
schedule of irinotecan (7.5mgkg
 1 per day) significantly improved survival (Po0.0001) in all three xenograft models. Combining
O6-BG and/or TMZ with irinotecan further enhanced survival.
CONCLUSION: Our in vitro and in vivo findings suggest that irinotecan drives the activity of irinotecan and TMZ in recurrent
neuroblastoma. Inhibitors of MGMT warrant further investigation for enhancing the activity of regimens that include TMZ.
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Neuroblastoma is the most common extracranial solid tumour
of childhood. Myeloablative chemotherapy followed by hemato-
poietic stem-cell transplantation and then 13-cis retinoic acid
(Matthay et al, 1999) or most recently anti-GD2 antibody and
cytokines (Yu et al, 2009) improve survival of children with
high-risk neuroblastoma, but many patients still die of progres-
sive disease. Therefore, the development of new therapies is a
priority.
Irinotecan, a topoisomerase I inhibitor, is a semi-synthetic
water-soluble analogue of camptothecin, a pro-drug that
undergoes de-esterification to an active metabolite, SN-38.
Irinotecan, as a single agent, has shown activity in vitro (Keshelava
et al, 2000) and in xenograft neuroblastoma models (Vassal et al,
1996; Thompson et al, 1997; Furman et al, 1999), and demon-
strated some objective responses in neuroblastoma patients treated
with various doses and schedules (Furman et al, 1999; Blaney et al,
2001; Kushner et al, 2005; Bomgaars et al, 2006, 2007). Preclinical
data from rhabdomyosarcoma and neuroblastoma xenograft
models have demonstrated schedule-dependent activity for irino-
tecan, with superior activity seen when using protracted low-dose
administration (Houghton et al, 1995).
Temozolomide (TMZ), a DNA methylating imidazole tetrazi-
none, inhibits cell growth in neuroblastoma xenografts
(Middlemas et al, 2000) and has been shown to have activity in
high-risk neuroblastoma patients (De et al, 2006; Rubie et al,
2006). It has been hypothesised that the cytotoxic activity of
TMZ is mediated through reactive O
6-methylguanine in DNA
(Tisdale, 1987); thus, inhibition of O
6-methylguanine-DNA
methyltransferase (MGMT), a DNA repair protein at the
O
6-guanine position, may increase the cytotoxicity of TMZ against
neuroblastomas (Wagner et al, 2007b). O
6-benzylguanine (O6-BG)
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sis a potent suppressor of MGMT activity, acting as a substrate for
MGMT (Dolan et al, 1990).
Irinotecan is commonly used in combination with TMZ to treat
recurrent high-risk neuroblastomas (Wagner et al, 2009) because
of their synergistic interaction in xenograft models (Houghton
et al, 2000), and their activity in patients with Ewing sarcoma
(Wagner et al, 2007a) and high-grade glioma (Reardon et al, 2005).
Clinically, these agents are administered sequentially, starting with
TMZ, because of the schedule-dependent activity demonstrated in
xenograft models. It is presumed that the placement of an adduct
at the O
6 position of guanine by an alkylating agent, such as BCNU
or TMZ, is critical for achieving synergistic activity with irinotecan
(Castellino et al, 2000).
The purpose of the current study was to assess the activity of
the TMZ and irinotecan combination in neuroblastoma pre-
clinical models and to determine whether inhibition of MGMT
by O6-BG significantly enhanced the anti-tumour activity of the
combination.
MATERIALS AND METHODS
Drugs and chemicals
Both TMZ and O6-BG were obtained from the Drug Synthesis and
Chemistry Branch, Developmental Therapeutics Program, National
Cancer Institute (Bethesda, MD, USA). SN-38 was purchased from
Abatra Technology Co., Ltd, and irinotecan was purchased from
the pharmacy at Childrens Hospital Los Angeles. Fluorescein
diacetate was purchased from Eastman Kodak Company
(Rochester, NY, USA), and eosin Y was from Sigma Chemical
Co. (St Louis, MO, USA). Antibodies were purchased from
various manufacturers: anti-MGMT monoclonal MT 3.1 Ab-1
from NeoMarkers (Fremont, CA, USA), caspase-3 (Cat# 9665) and
phospho-H2AX (Ser 139, Cat# 9718) rabbit monoclonal antibody
from Cell Signaling Technology (Danvers, MA, USA) and F7-26
from Chemicon International (Temecula, CA, USA).
Cell Lines
We used four drug-sensitive (SMS-SAN, CHLA-42, CHLA-15 and
SMS-KCNR) and seven multidrug-resistant (CHLA-171, CHLA-
136, SK-N-RA, SK-N-BE(2), CHLA-90, CHLA-119 and CHLA-172)
cell lines. CHLA-136 and SK-N-RA cell lines carry wild type and
transcriptionally active TP53 (Keshelava et al, 2001). SK-N-BE(2),
CHLA-90, CHLA-119 and CHLA-172 carry mutant and transcrip-
tionally inactive TP53 (Keshelava et al, 2001). CHLA-171 carries
wild type, but transcriptionally inactive TP53, likely because of the
MDM2 protein overexpression (Keshelava et al, 2001).
SMS-KCNR cells were grown in RPMI-1640 supplemented
with 10% heat-inactivated fetal bovine serum (Omega Scientific,
Tarzana, CA, USA). All other cells were grown in Iscove’s Modified
Dulbecco’s Medium (Biowhittaker, Walkersville, MD, USA)
supplemented with 20% fetal bovine serum, 3mML -Glutamine
(Mediatech, Inc., Herndon, VA, USA) and 0.1% premium ITS
culture supplement containing 5mgml
 1 insulin, 5mgml
 1 trans-
ferrin and 5ngml
 1 selenious acid (VWR Scientific, West Chester,
PA, USA). The cell lines were cultured without antibiotics at 371C
in a humidified incubator containing 95% air and 5% CO2
atmosphere. All cell lines tested negative for mycoplasma. Cell
lines were not selected for drug resistance in vitro. The identities of
all cell lines were confirmed by a short tandem repeat assay
(Masters et al, 2001).
TaqMan RT-PCR
TaqMan real-time reverse transcription-PCR (RT-PCR) was used
to quantify RNA with the Sequence Detection System (ABI Prism
model 7700; Applied Biosystems, Foster City, CA, USA). The probe
and primer for MGMT gene were purchased from Applied
Biosystems (Cat# Hs00172470).
Reactions were performed with 150ng of RNA in the Master Mix
prepared from the kit, TaqMan one-step RT-PCR Master Mix
Reagents (Applied Biosystems, Branchburg, NJ, USA), in a final
volume of 25ml. Three replicates for each reaction were plated
into 96-well plates. RT-PCR assay was performed under the
following conditions: 2min at 501C, 10min at 951C, 40 cycles
of denaturation at 951C for 15s and annealing/extension at 601C
for 1min. The RNA of each sample was normalised to the level
of GAPDH.
Cytotoxicity assay
We determined the cytotoxicity of O6-BG, irinotecan and TMZ,
as single drugs or in combination, in the CHLA-15, CHLA-42,
SMS-KCNR, CHLA-136 and CHLA-90 cell lines by DIMSCAN
(Keshelava et al, 2005; Frgala et al, 2007), a semiautomatic
fluorescence-based digital image microscopy system that quanti-
fies viable cells in tissue culture multi-well plates on the basis of
their selective accumulation of fluorescein diacetate. DIMSCAN is
capable of measuring cytotoxicity over a four-log dynamic range
by quantifying total fluorescence per well, which is proportional
to the number of viable, clonogenic cells after eliminating
background fluorescence with digital thresholding and eosin Y
quenching (Keshelava et al, 2005; Frgala et al, 2007).
Briefly, cell lines were seeded into 96-well plates in 150mlo f
complete medium (1500–3500 cells per well) and incubated
overnight. O6-BG (25mM)i n5 0ml of complete medium was added
to each well. After an, additional, 24-h incubation, TMZ
(0–50mgml
 1) and SN-38, an active in vitro metabolite of
irinotecan (0–20ngml
 1), were added. We chose a range of
concentrations for TMZ and SN-38 that would encompass drug
levels active in pre-clinical models and clinically relevant.
Protracted administration of low-dose irinotecan in children
resulted in a Cmax of B20ngml
 1 (Ma et al, 2000), a level that
was cytotoxic to neuroblastoma cells (Keshelava et al, 2000). The
clinically achievable level of TMZ in children is 13±2.8mgml
 1
(Horton et al, 2007) and in xenograft models, TMZ Cmax is
36mgml
 1 (Houghton et al, 2000). Each drug concentration was
tested in 12 replicate wells. Cell lines were incubated in the
presence of these agents for 72h, after which fluorescein diacetate
in 50ml of 0.5% eosin Y (final concentration of fluorescein
diacetate¼10mgml
 1) was added to each well and cells were
incubated for an additional 25min at 371C. Total fluorescence was
then measured with the use of DIMSCAN as previously described
(Keshelava et al, 2005; Frgala et al, 2007), and results were
expressed as surviving fractions of treated cells compared with
control cells that were exposed to vehicle solution alone.
In addition to simultaneous administration of TMZ and SN-38,
we also tested sequential administration of these drugs in the
CHLA-15, SMS-KCNR and CHLA-90 cell lines. In these experi-
ments, TMZ was added to cells 3h before irinotecan.
ssDNA damage measurements with F7-26 antibody
Cells were treated with O6-BG (25mM, 24h), TMZ (50mgml
 1, 6h),
SN-38 (20ngml
 1, 4h) or their combinations, and analysed after
overnight fixation in methanol–PBS (6:1). Staining with F7-26
monoclonal antibody was performed according to the manufac-
turer’s instructions. Flow cytometry was performed on a BD LSR II
flow cytometer (BD Biosciences, San Jose, CA, USA) and data were
acquired and analysed using BD FACSDiva software.
Immunoblot analysis of protein expression
Cells from three drug-sensitive cell lines (SMS-KCNR, SMS-SAN
and CHLA-42) and seven multidrug-resistant cell lines (CHLA-171,
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sCHLA-136, SK-N-RA, SK-N-BE(2), CHLA-90, CHLA-119 and
CHLA-172) were grown to 70% confluence in 75cm
2 flasks and
then lysed in immunoprecipitation assay buffer (50mM NaCl,
50mM Tris (pH 7.4), 1% Triton X-100, 1% sodium deoxycholate,
0.1% sodium dodecyl sulphate). Total protein (30mg per lane) was
fractionated on 10% tris-glycine precast gels (Novex, San Diego,
CA, USA), transferred to nitrocellulose membrane (Protran, Keene,
NH, USA), and probed with primary antibodies at a 1:1000 dilution,
followed by incubation with an HRP-conjugated secondary
antibody. The membranes were incubated with SuperSignal West
Pico chemiluminescent substrate (Pierce Biotechnology, Inc., Rock-
ford, IL, USA), and protein: antibody complexes were detected by
autoradiography (Denville Scientific, Inc., Metuchen, NJ, USA).
H2AX expression, phosphorylated at Ser 139, was assessed in
CHLA-15 cells for characterisation of DNA double strand breaks.
Similar doses and schedules were tested as with F7-26 monoclonal
antibody staining.
Animals
Athymic (nu/nu) female mice, 6–7 weeks old (Harlan Labora-
tories, Inc., San Diego, CA, USA) were used in the study. Mice were
housed in an air-conditioned room and fed the standard
laboratory chow. All procedures were performed in compliance
with the Childrens Hospital Los Angeles Institutional Animal Care
and Use Committee-approved protocols.
Mouse models of mass disease
We used the SMS-KCNR, CHLA-136 and CHLA-119 neuroblasto-
ma cell lines for the xenograft experiments. These cell lines were
chosen to represent neuroblastomas that were: (a) drug-sensitive
(SMS-KCNR), (b) multidrug-resistant with wild-type and trans-
criptionally active TP53 (CHLA-136) and (c) multidrug-resistant
with mutant and transcriptionally inactive TP53 (CHLA-119)
(Keshelava et al, 2001). Treatments began when tumours reached
200mm
3. Tumour measurements were made twice a week. Once
tumour reached 1500mm
3, mice were humanely sacrificed.
Treatment protocol
Drugs were given as follows: O6-BG (30mgkg
 1 delivered through
intraperitoneal injections) was followed 1h later by TMZ
(25mgkg
 1 given by oral gavage) and 1h later by irinotecan
(7.5mgkg
 1 given by tail vein injection). O6-BG was dissolved in
4% DMSO, 30% PEG-400 and 66% saline, TMZ was dissolved in
water, and irinotecan in saline. Control mice were administered
sterile carrier solutions. Mice were treated on a 1-week on (5 days)-
2 weeks off schedule for four cycles. The doses of administered
drugs were chosen following determination of the maximum
tolerated dose. The administered drugs at the doses reported here
were well tolerated; no weight loss, diarrhea or abnormal behaviour
was observed. White blood cell count was not monitored.
Data analysis
IC90 (drug concentrations that were cytotoxic or growth inhibitory
for 90% of the cell population), and dose reduction index values
were calculated using CalcuSyn software (Biosoft, Cambridge, UK)
(Chou and Talalay, 1984).
The association between log-transformed RT-PCR values for
MGMT RNA expression and immunoblot values for MGMT
protein expression was assessed by calculating the Pearson’s
correlation coefficient. All P-values are two-sided. The computa-
tions of the Pearson’s correlation coefficient were performed with
the use of STATA software (version 9.0; College Station, TX, USA).
A P-value of less than or equal to 0.05 was considered statistically
significant.
The effect of TMZ pre-treatment was studied by comparing
dose–response curves of the TMZ and irinotecan combination,
in the presence or absence of O6-BG, with those drugs administered
simultaneously or sequentially. The difference in the cytotoxic effect
was examined by comparing the area between the dose–response
curve and the 100% survival line. Statistical analysis assumed that
the difference between the untreated controls and the highest drug
concentration was 1. The fixed ratio design of the cytotoxicity
experiments allowed the concentration increments to be quantitated
at 1/8, 1/4, 1/2 and 1. The area between the survival curves for each
treatment group and the 100% survival line was viewed as the sum
of areas of four trapezoids, computed as:
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1
2
 ð F0k þ  F1kÞ 
1
8
þ
1
2
 ð F1k þ  F2kÞ 
1
8
þ
1
2
 ð F0:2k þ  F3kÞ 
1
4
þ
1
2
 ð F0:3k þ  F4kÞ 
1
2
¼
1
16
  F0k þ
1
8
  F1k þ
3
16
  F2k þ
3
8
  F3k þ
1
4
  F4k
R
e
l
a
t
i
v
e
 
M
G
M
T
 
e
x
p
r
e
s
s
i
o
n
2.0
1.2
1.6
0.4
0.8
0.0
12 3 4 5 6 7 8 9 1 0
-Actin
MGMT
R
e
l
a
t
i
v
e
 
t
o
 

−
a
c
t
i
n
SMS-SAN
CHLA-42
SMS-KCNR
CHLA-171
CHLA-136
SK-N-RA
SK-N-BE-2
CHLA90
CHLA-119
CHLA-172
1.2
1.6
2.0
0.4
0.8
0.0
1 56 1 0 9 8 7 3 2 4
Figure 1 O
6-methylguanine-DNA methyltransferase (MGMT) expres-
sion in drug-sensitive (white bars) and multidrug-resistant neuroblastoma
cell lines (black bars). Lanes, 1 – SMS-SAN, 2 – CHLA-42, 3 – SMS-KCNR,
4 – CHLA-171, 5 – CHLA-136, 6 – SK-N-RA, 7 – SK-N-BE(2), 8 – CHLA-
90, 9 – CHLA-119 and 10 – CHLA-172. (A) Quantification of mRNA
expression for the MGMT gene by TaqMan reverse transcription–
polymerase chain reaction in a panel of 10 neuroblastoma cell lines.
Mean mRNA expression (normalised to GAPDH mRNA expression)
and standard deviations (error bars) from three replicates are shown.
(B) Upper panel: Immunoblot analysis of MGMT protein expression,
equal protein loading was confirmed by immunoblot analysis of b-actin
expression. Bottom panel: quantitative analysis of MGMT protein
expression as a ratio to b-actin expression.
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swhere  Fjk is the mean fraction of logs of cell kill after treatment at
the jth dose (0th, 1st, 2nd, 3rd and 4th drug conditions). The linear
combination:
1
16
 ð F0i    F0jÞþ
1
8
 ð F1i    F1jÞþ
3
16
 ð F2i    F2jÞþ
3
8
 ð F3i    F3jÞþ
1
4
 ð F4i    F4jÞ
then tested the difference in treatment effects between two
dose–response curves (designated as i and j). Data were analysed
with software SAS Version 9.1 (College Station, TX, USA).
For xenograft studies, the main effects of the three drugs
(O6-BG, TMZ and irinotecan) on the length of survival of mice, as
well as their second- and third-order interactions (e.g., enhancement
of the effect of one drug with addition of another) were evaluated
using censored regression models as implemented in the
CNREG routine of STATA 9.0 (StataCorp LP, College Station,
TX, USA). Days of survival were assumed to have a lognormal
distribution, and the days were transformed to the natural log scale
before analyses were carried out. O6-BG, TMZ and irinotecan, as
well as their second- and third-order interaction terms were
included in the initial regression model. For main drug effects,
a P-value less than or equal to 0.05 was considered statistically
significant. For test of interaction effect between drugs (e.g.,
enhancement in the effect of one drug with addition of another),
a P-value less than or equal to 0.01 was considered statistically
significant. P-values from likelihood ratio tests are presented. To
compare the length of survival between any two groups of mice,
a censored regression model was first fit using data from all the
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Figure 2 Effect of the temozolomide and SN-38 combination in the presence of O
6-methylguanine-DNA methyltransferase (MGMT) inhibitor in
neuroblastoma cell lines obtained by DIMSCAN assay. For MGMT inhibition, cells were pretreated with 25mM O
6-benzylguanine (O6-BG) for 24h,
temozolomide and/or SN-38 were then added for an additional 3 days. Dose–response curves for temozolomide alone (J), temozolomide in the
presence of O6-BG (*), SN-38 alone (&), SN-38 in the presence of O6-BG (’), temozolomide and SN-38 ( ) and temozolomide and SN-38 in the
presence of O6-BG (.) were obtained by DIMSCAN assay.
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streatment groups with the CNREG routine, then difference in mice
survival between two treatment groups was evaluated by testing the
appropriate linear combinations using the STATA LINCOM
command. Data from the three cell lines was analysed separately.
All P-values reported were two-sided.
RESULTS
MGMT RNA and protein expression
Around 10 neuroblastoma cell lines (SMS-SAN, SMS-KCNR,
CHLA-42, CHLA-171, CHLA-136, SK-N-RA, SK-N-BE(2),
CHLA-90, CHLA-119 and CHLA-172) were tested for MGMT
RNA and protein expression by TaqMan RT-PCR and immuno-
blotting, respectively (Figure 1A and B). All cell lines, except
CHLA-90, expressed MGMT. MGMT RNA expression correlated
significantly with MGMT protein expression (r¼0.67, Po0.03).
Thus, MGMT is expressed in neuroblastomas and may be a
pharmacological target for therapeutic regimens that include TMZ,
as previously suggested (Wagner et al, 2007b).
Cytotoxicity of O6-BG, TMZ and irinotecan in
neuroblastoma cell lines
Next, we examined whether O6-BG can increase the activity of
TMZ or the TMZ and irinotecan combination in neuroblastomas
using three drug-sensitive (CHLA-15, CHLA-42 and SMS-KCNR)
and two multidrug-resistant (CHLA-90 and CHLA-136) cell lines,
including the one that does not express MGMT (CHLA-90)
(Figures 2 and 3). For these in vitro experiments, O6-BG was
tested at 25mM, a concentration chosen on the basis of the studies
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Figure 3 Cytotoxicity of sequentially or simultaneously administered temozolomide and SN-38 in neuroblastoma cell lines measured by the DIMSCAN
assay. Cells were pretreated with 25mM O
6-benzylguanine (O6-BG) for 24h, temozolomide and SN-38 were then added for an additional 3 days.
Temozolomide was added 3h before or simultaneously with SN-38. Dose–response curves for temozolomide and SN-38 administered simultaneously ( )
or sequentially ( ), temozolomide and SN-38 administered simultaneously in the presence of O6-BG (.), temozolomideþSN-38 administered
sequentially in the presence of O6-BG ( ).
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sdemonstrating significant reduction of MGMT enzymatic activity
in vitro by O6-BG at 10mM (Bacolod et al, 2002). Depletion of
MGMT protein by 75mM O6-BG has also been demonstrated
(Murakami et al, 2007). Using western blotting, we confirmed
reduced protein expression following treatment with 25mM O6-BG
in the SMS-KCNR and CHLA-136 cell lines (data not shown).
Figure 2 shows the dose–response curves obtained from the
DIMSCAN assay. We calculated the concentrations that were
growth inhibitory or cytotoxic for 90% of treated cells (IC90) for
single drugs or drug combinations using the dose–response curves
for TMZ, SN-38 and TMZ and SN-38 in the presence or absence of
25mM O6-BG.
The single-agent IC90 values for TMZ ranged from 27 to
450mgml
 1 (Table 1). Addition of 25mM O6-BG enhanced the
growth inhibitory effect of TMZ by up to 1.4 logs in CHLA-15, 0.6
logs in CHLA-42, 0.9 logs in SMS-KCNR and 0.3 logs in CHLA-136
cells (Figure 2). The single-agent IC90 values for SN-38 ranged
from o2.5 to 420ngml
 1 (Table 1). Addition of 25mM O6-BG
marginally enhanced growth inhibitory effect of SN-38 in the
CHLA-42 cell line. The TMZ and SN-38 anti-neuroblastoma
activity was tested at a fixed ratio of 2.5:1. The growth inhibitory
activity of the combination was SN-38 driven in all tested lines.
Addition of 25mM O6-BG increased TMZ and SN-38-mediated
growth inhibition by up to 0.6 logs in CHLA-42 and 0.5 logs in
SMS-KCNR cell lines (Figure 2).
As TMZ is given before irinotecan to neuroblastoma patients, we
examined whether administration of TMZ 3h before SN-38
exposure would result in higher cytotoxicity in representative
neuroblastoma cell lines: CHLA-15, SMS-KCNR and CHLA-90.
Comparison of the dose–response curves of TMZ and SN-38 in the
presence or absence of O6-BG, with the drugs administered
simultaneously or sequentially, did not reach statistical signifi-
cance (Figure 3).
DNA damage in vitro
Single- or double-strand (ss or ds) DNA breaks caused by the
tested drugs and drug combinations were measured in a
representative neuroblastoma cell line (CHLA-15), selected for its
propensity to grow in single-cell suspension that does not clump
excessively. F7-26 monoclonal antibody staining to single-stranded
DNA was used to quantify ssDNA damage (Figure 4A and B). We
have previously shown that this method distinguishes ssDNA
breaks caused by exogenous stimuli from DNA strand breaks
resulting from apoptosis (Grigoryan et al, 2007). Phosphorylation
of the H2A histone variant, H2AX, at serine-139 was used to
quantify dsDNA damage (Figure 4C).
SN-38 induced more prominent single-strand (4.3-fold higher
F7-26 staining) or double-strand (84-fold higher expression of
pS
139-H2AX) DNA damage, compared with TMZ (ssDNA¼two-
fold, dsDNA¼11-fold) or O6-BG (ssDNA¼1 and dsDNA¼4).
Significantly more ssDNA damage was achieved by any of the two
drug combinations (O6-BG and TMZ, O6-BGþSN-38 and TMZ
and SN-38, P-values o0.001) relative to simple addition of single
drug actions as measured by linear regression analysis. Synergistic
induction of ssDNA breaks was not demonstrated for the triple
drug combination. Thus, the data show that increased DNA
damage by the two- and three-drug combinations results mostly
from the breakage induced by SN-38, although TMZ and/or O6-BG
further enhanced DNA breaks.
Activity in the mouse xenograft models
First, we confirmed that the planned dosing schedule achieved
the desired pharmacodynamic effect on the xenograft tumours.
SMS-KCNR mice were treated with O6-BG or/and TMZ for 1 week
and sacrificed. Tumour tissues were obtained and MGMT deple-
tion by O6-BG was demonstrated by immunoblotting (Figure 5A),
whereas induction of apoptosis was verified by cleavage of
caspase 3 (Figure 5B).
Formal factorial design was applied to our xenograft
studies for comprehensive assessment of contributions of single
drugs or two-drug combinations to the anti-tumour activity
obtainable by the O6-BG, TMZ and irinotecan combination
(Table 2).
TMZ as a single agent did not have any significant effect on
survival of either SMS-KCNR (P¼0.21), CHLA-136 (P¼0.81) or
CHLA-119 (P¼0.9) xenografts; however, addition of O6-BG
resulted in significant evidence of enhancement of TMZ effect in
SMS-KCNR xenografts (P¼0.002). This enhancement was margin-
ally significant in CHLA-119 (P¼0.018) xenografts.
O6-BG, as a single agent, significantly improved survival of the
CHLA-136 xenografts (P¼0.007). When administered as single
agents, TMZ and O6-BG did not show significant difference in
mean survival days in SMS-KCNR (P¼0.29) or CHLA-119
(P¼0.13) xenografts, but showed significant difference in
CHLA-136 (P¼0.028).
Irinotecan delivered the most activity among the treated groups
(Figure 6). As a single agent, irinotecan significantly improved the
survival rate (Po0.0001) in all three xenograft models. Addition of
TMZ (Figure 6) or O6-BG did not significantly improve irinotecan
activity. In contrast, addition of O6-BG to the TMZ and irinotecan
combination significantly increased survival days of SMS-KCNR
(P¼0.017), CHLA-136 (P¼0.033) and CHLA-119 (P¼0.017)
Table 1 IC values for TMZ and SN-38, and DRI values for their combination in the absence or presence of O6-BG at the 90% growth inhibition
DRI
a DRIO6-BG
b
Cell line
IC90
TMZ (lgml
 1) +O6-BG
c
IC90
SN-38 (ngml
 1) +O6-BG
TMZ
(+SN38)
SN-38
(+TMZ)
TMZ
(+SN38)
SN-38
(+TMZ)
CHLA-15 31.2 7.2 o2.5 o2.5 45.0 ND
d ND ND
CHLA-42 450
e 450 14 7.2 43.3 2.3 48 42.9
SMS-KCNR 27.2 o6.25 o2.5 o2.5 44.3 ND ND ND
CHLA-136 450 450 6.7 9.3 42 0.7 46.8 0.9
CHLA-90 450 450 420 420 ND ND ND ND
Abbreviations: DRI¼dose reduction index; IC90¼drug concentrations that were cytotoxic or growth inhibitory for 90% of the cell population; ND¼not determined;
O
6-BG¼O
6-benzylguanine; TMZ¼temozolomide.
aDRI reflects the fold reduction in the required concentration of tested agents when used in combination to achieve 90% cell
death and/or growth inhibition.
bDRI for drugs determined in the presence of 25mM O6-BG.
cIC90 values for temozolomide or SN-38 calculated in the presence of 25mM O6-
BG.
dDRI was not determined as over 90% cell death and/or growth inhibition was achieved by a single drug (SN-38 or TMZ) at the concentration that was lower (o2.5ngml
 1
or o6.25mgml
 1) than that tested. DRI was also not determined when 90% cell death and/or growth inhibition was not achieved by drug combination.
eIf 90% cell death and/or
growth inhibition was not achieved at the tested concentrations, then the IC90 values were reported as ‘4 the highest-tested concentration’. The highest concentrations tested
were: 50mgml
 1 for temozolomide and 20ngml
 1 for SN-38. Similarly, if 90% cell death and/or growth inhibition was achieved at the concentrations lower than that tested,
then the IC90 values were reported as ‘o the lowest-tested concentration’. The lowest concentrations tested were: 6.25mgml
 1 for temozolomide and 2.5ngml
 1 for SN-38.
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Figure 4 Assessment of single- and double-stranded DNA damage by O
6-benzylguanine (O6-BG), temozolomide, irinotecan and their combinations in
a representative neuroblastoma cell line. CHLA-15 cells were treated with O6-BG (25mM, 24h), temozolomide (TMZ, 50mgml
 1, 6h), and SN-38
(20ngml
 1, 4h). (A) Single-strand breaks were quantified by F7-26 monoclonal antibody using flow cytometric assay. Each condition was examined as three
replicates. (B) Quantification of single-strand DNA breaks as measured by flow cytometry. Mean values and standard deviation were calculated from three
replicates. (C) The marker of double-strand DNA-damage, H2AX phosphorylated at Ser 139 (15kDA), was measured by immunoblotting. Equal protein
loading was confirmed by immunoblot analysis of b-actin expression. Upper panel: immunoblot analysis of pH2AX expression. Bottom panel: quantitative
analysis of pH2AX protein expression as a ratio to b-actin expression. Lanes: 1 – untreated controls, 2 – TMZ, 3 – SN-38, 4 – O6-BG, 5 – TMZ and SN-38,
6 – TMZ and O6-BG, 7 – SN-38 and O6-BG and 8 – Triple.
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sxenografts (Figure 6). Notably, 60% of the CHLA-119 xenografts
were still alive at 400 days, indicating a significant effect on
survival of the O6-BG, TMZ and irinotecan combination.
DISCUSSION
The combination of TMZ, a DNA methylating agent, with
irinotecan, a topoisomerase I inhibitor, had emerged as a
promising regimen for recurrent neuroblastoma (Kushner et al,
2006; Wagner et al, 2009). However, recent evidence suggests that
the effectiveness of TMZ in neuroblastomas can be diminished
by MGMT-mediated DNA damage repair (Middlemas et al, 2000;
Wagner et al, 2007b). MGMT is frequently expressed in
neuroblastoma tumours and cell lines (Middlemas et al, 2000;
Wagner et al, 2007b). MGMT methylation in the promoter region
has also been examined in neuroblastomas as promoter hyper-
methylation is associated with decreased MGMT expression. In
those studies, promoter hypermethylation ranged from 0 to 27% in
the examined tumours and cell lines (Harada et al, 2002; Gonzalez-
Gomez et al, 2003; Lazcoz et al, 2007). Depletion of MGMT activity
by the selective inhibitor, O6-BG, reportedly enhanced the
cytotoxicity of TMZ in human brain tumour (Bobola et al, 1996)
and melanoma (Wedge et al, 1997) xenografts. O6-BG also
enhanced the anti-tumour activity of the TMZ and irinotecan
combination in a model of disseminated neuroblastoma (Wagner
et al, 2007b) and glioma xenograft models (Friedman et al, 2002).
MGMT
1
Caspase 3
Cleaved
caspase 3
-Actin
-Actin
4 3 2
14 3 2
Figure 5 Assessment of pharmacodynamic markers of O
6-benzyl-
guanine (O6-BG) and temozolomide activity. (A) SMS-KCNR cells were
established as subcutaneous (s.c.) xenografts in nu/nu mice. Expression
of O
6-methylguanine-DNA methyltransferase was determined in tumour
tissue following 5 days of administration of O6-BG at 30mgkg
 1 each day.
(B) Pro-caspase 3 (35kDa) and cleaved caspase 3 (19 and 17kDa) were
measured by immunoblotting in tumour tissues of SMS-KCNR xenografts
after daily administration of O6-BG and/or temozolomide (25mgkg
 1) for
5 days. Lanes: 1 – controls, 2 – mice treated with O6-BG, 3 – mice treated
with temozolomide, 4 – mice treated with the combination of O-6BG and
temozolomide. Equal protein loading was confirmed by immunoblot
analysis of b-actin expression.
Table 2 Survival of neuroblastoma xenografts in response to TMZ and/or IRN in the presence or absence of O6-BG
SMS-KCNR CHLA-136 CHLA-119
Treatment N
a Mean days
b (95% CI
c) N Mean days (95% CI) N Mean days (95% CI)
Control 10
d 16.6 (11.9, 23.3) 11 20.7 (14.9, 28.8) 10 29.7 (23.3, 37.3)
O6-BG 5 19.3 (13.2, 27.9) 6 32.8 (25, 42.9) 5 25.0 (18, 34.8)
TMZ 5 16.0 (11.4, 22.4) 5 21.3 (13.6, 33.1) 5 37.7 (10.9, 131.6)
IRN 5 100.5 (85.6, 119.1) 5 146.9 (86.6, 249.1) 5 239.2 (166.3, 344.2)
O6-BG+TMZ 5 45.6 (35.2, 59.7) 6 27.7 (18.4, 41.7) 5 53.5 (46.1. 62.2)
O6-BG+IRN 5 100.5 (83.9, 120.3) 5 121.5 (108.9, 134.3) 4 215.3 (131.6, 352.3)
TMZ+IRN 10 125.2 (109.9, 144) 11 122.7 (113.3, 131.6) 5 181.3 (121.5, 270.4)
Triple 5 186.2 (119.8, 289.6) 6 173.5 (132.8, 226.8) 5 361.4 (198.1, 659.4)
Abbreviations: IRN¼irinotecan; O6-BG¼O
6-benzylguanine; TMZ¼temozolomide.
aNumber of mice evaluated.
bGeometric average day for tumours to reach 1500mm
3.
The mean survival days and 95% confidence intervals take into account the censored mice (those that were alive at the last follow-up date and did not have tumour equal or
above 1500mm
3). The maximum likelihood analysis was used to perform calculations (http://www.weibull.com/LifeDataWeb/analysis_parameter_methods.htm).
cConfidence
intervals.
dExperiments for each xenograft line were split in two parts conducted in short succession (1–2 months apart) and, therefore, two sets of the control mice were used
for each xenograft. The combination of temozolomide and irinotecan was tested twice in SMS-KCNR and CHLA-136 xenografts to confirm the reproducibility of our findings
in the models.
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Figure 6 Human neuroblastoma cell lines SMS-KCNR, CHLA-119 and CHLA-136 were established as s.c. xenografts in nu/nu mice. Animals received
O
6-benzylguanine (O6-BG, 30mgkg
 1) followed 1h later by temozolomide (TMZ, 25mgkg
 1) and 1h later by irinotecan (IRN, 7.5mgkg
 1). Control mice
were administered sterile carrier solutions. Mice were treated for 5 days every 3 weeks for four cycles. Animals were sacrificed when tumours reached
1500mm
3. Survival probability of mice treated with vehicle control (pink lines), O6-BG and TMZ (gray lines), IRN (green lines), TMZ and IRN (blue lines),
O6-BG, TMZ and IRN (red lines) are shown.
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sWe undertook this large-scale study to formally assess the anti-
tumour activities of O6-BG, TMZ and irinotecan, as well as their
second- and third-order interactions (such as enhancement of one-
drug effect with addition of another) in neuroblastoma pre-clinical
models. To our knowledge, such extensive assessment has not been
carried out previously.
In our study, 10 neuroblastoma cell lines were examined
for MGMT RNA and protein expression. All expressed MGMT,
except the multidrug-resistant cell line, CHLA-90, which carries
a TP53 mutation (Keshelava et al, 2001). This is consistent with
a report showing that promoter methylation of the MGMT
gene (which results in low or absent MGMT expression) is
associated with an increased frequency of TP53 mutations
(Nakamura et al, 2001).
We have evaluated the anti-neuroblastoma activity of O6-BG,
TMZ and irinotecan in vitro and in vivo. Drug levels used for
O6-BG decreased MGMT protein expression both in vitro (data not
shown) and in vivo (Figure 5A). Our in vitro data confirmed that
O6-BG enhanced the cell sensitivity to TMZ. Pre-treatment with
25mM O6-BG sensitised four out of the five tested neuroblastoma
cell lines to TMZ by 0.3–1.4 logs (Figure 2); sensitising effect was
not demonstrated in the highly drug-resistant CHLA-90 cells that
lack MGMT expression. In xenografts, O6-BG as a single agent had
a significant effect on the survival of CHLA-136 tumour-bearing
mice (P¼0.007). O6-BG significantly enhanced TMZ activity in
SMS-KCNR (P¼0.002) and marginally in CHLA-119 (P¼0.018)
mice.
Temozolomide, either alone (Rubie et al, 2006) or in combina-
tion with irinotecan (Wagner et al, 2009), is being actively
investigated as a possible first-line regimen for recurrent
neuroblastomas. In our study, single agent TMZ did not have a
significant effect on the survival of either SMS-KCNR, CHLA-136
or CHLA-119 xenografts at the administered dose and
schedule. We carefully selected the drug levels for our in vitro
(0–50mgml
 1) and xenograft experiments (25mgkg
 1 per day),
on the basis of the previously reported pre-clinical and clinical
pharmacokinetic data of TMZ. The pharmacokinetic studies by
Stevens et al, and Houghton et al, conducted in mice, demon-
strated that oral administration of 20mgkg
 1 or 66mgkg
 1
temozolomide resulted in a Cmax of 19.6mgml
 1 (Stevens et al,
1987) or 36mgml
 1 (Houghton et al, 2000), respectively. The
TMZ Cmax levels achievable in children are in the range of
5.6±1.8mgml
 1 (Baruchel et al, 2006) to 13±2.8mgml
 1 (Horton
et al, 2007). Thus, administration of 25mgkg
 1 per day TMZ in
mice would result in a systemic exposure well within the clinically
relevant drug levels. By demonstrating caspase 3 activation, a
hallmark of apoptosis (Figure 5B), in SMS-KCNR xenografts, we
confirmed the suitability of the administered drug dose.
Irinotecan, as a single-agent, had substantial activity in vitro in
four neuroblastoma cell lines, achieving 1.1–2.8-log cytotoxicity at
20ngml
 1 (achievable in patients, Vassal et al, 2003), and in our
xenograft models. Our results are in agreement with other pre-
clinical investigations of irinotecan that demonstrated activity
against neuroblastomas (Komuro et al, 1994; Vassal et al, 1996;
Thompson et al, 1997; Furman et al, 1999). However, phase II
clinical trials of single-agent irinotecan have only shown limited
activity in neuroblastoma patients (Bomgaars et al, 2007; Vassal
et al, 2008). Such divergence could be attributed to the disparate
metabolism of irinotecan into its active metabolite SN-38 in
different species. It is estimated that mouse liver and kidney
carboxylesterase more actively hydrolyses irinotecan than either
human carboxylesterase1 (hCE1) (173 vs 2.5pmolmg
 1min
 1
activity) (Xie et al, 2003) or hCE2, a more potent activator of
irinotecan than human carboxylesterase1 (Humerickhouse et al,
2000). Nonetheless, the strong anti-neuroblastoma activity
achieved by irinotecan in all our three xenograft models warrants
further testing of irinotecan with additional agents to identify
synergistic combinations against recurrent neuroblastomas.
In contrast to previous pre-clinical investigations of TMZ
and irinotecan in neuroblastoma xenograft models (Houghton
et al, 2000), our studies did not demonstrate synergy between
these drugs. The difference may be attributable to the use
in the studies by Houghton et al of dose levels of irinotecan
and TMZ that were unlikely to induce complete responses
when administered alone. In our study, standardised dose-
schedule for irinotecan and TMZ were used to mimic the
clinical application of O6-BG, TMZ and irinotecan in children.
In addition, the 5-day schedule for irinotecan instead of
the (dx5(x2)) schedule used by Houghton et al may have
also contributed to the different responses seen in these two
pre-clinical studies.
Previous studies have examined the effect of O6-BG on the
anti-tumour activity of the TMZ and irinotecan combination
in neuroblastomas (Wagner et al, 2007b) and in gliomas
(Friedman et al, 2002; Quinn et al, 2009). A recent phase I clinical
trial in adults with recurrent malignant glioma evaluated the
combination of O6-BG, TMZ and irinotecan, administered once
on 21-day schedule (Quinn et al, 2009). Although the primary
goal of the study was to define the maximum tolerated dose and
dose-limiting toxicity of the evaluated drugs, it did not demon-
strate any responses. The lack of responses was hypothesized
to be due to subtherapeutic doses or timing of administered
doses. Our in vivo studies, conducted in a mouse model of mass
disease, demonstrated significantly improved survival for xeno-
grafts treated with the TMZ and irinotecan combination in the
presence of O6-BG, in agreement with the findings by Wagner et al
in a mouse model of metastatic disease (Wagner et al, 2007b).
Our data suggest that the enhanced anti-neuroblastoma activity
by the triple combination resulted from significant irinotecan
activity together with the added benefit of statistically signi-
ficant O6-BG (in CHLA-136) or O6-BG and TMZ (in SMS-KCNR
and CHLA-119) activities. This is confirmed by the DNA studies
where single- or double-stranded DNA damage was mostly
due to SN-38 and further enhanced with the addition of TMZ
and/or O6-BG, emphasising the critical cytotoxic effect of
irinotecan in the combination. Moreover, we observed improved
survival at 400 days of the multidrug-resistant xenograft
CHLA-119 in contrast to the study by Wagner et al, in which
the apparent advantage of adding O6-BG to TMZ and irinotecan
seen at 100 days was lost at 300 days. The difference between
these two studies can be explained by the use of four cycles
of therapy in our study rather than two as employed by Wagner
et al, or it may be attributable to the utilisation of the different
strain of mice.
Our extensive in vitro and in vivo investigations using formal
factorial design allowed us to convincingly demonstrate in
neuroblastoma pre-clinical models that (a) irinotecan adminis-
tered on a protracted schedule has remarkable anti-tumour
activity; (b) MGMT inhibition enhances the anti-tumour activity
of TMZ, confirming MGMT as a relevant pharmacological target.
These data suggest that inhibition of MGMT should be further
investigated especially in regimens containing TMZ and identifica-
tion of new drug combinations for irinotecan are warranted for the
treatment of high-risk neuroblastomas.
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